Erschienen in:
01.03.2011 | Pancreatic Tumors
Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?
verfasst von:
Matthew H. G. Katz, MD, Peter W. T. Pisters, MD, Jeffrey E. Lee, MD, Jason B. Fleming, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 3/2011
Einloggen, um Zugang zu erhalten
Excerpt
In this issue of the
Annals of Surgical Oncology, Stokes et al. make an important contribution to the literature on borderline resectable pancreatic ductal adenocarcinoma (PDAC).
1 The investigators from the University of Virginia found that 46% of patients with borderline resectable PDAC (defined using a classification developed at the University of Texas M. D. Anderson Cancer Center [MDACC] over the past decade) completed a multidisciplinary treatment program of neoadjuvant capecitabine-based chemoradiation and surgery and that this group had an overall survival duration that was both favorable (median, 23 months) and similar to that of a historical cohort of patients with potentially resectable PDAC who underwent resection.
2,
3 These data, combined with those from series recently reported by Fox Chase Cancer Center and our own institution, provide strong support for the use of neoadjuvant treatment sequencing in patients with localized PDAC who would be at high risk for margin-positive resection and early treatment failure following a surgery-first strategy.
2,
4,
5 …
